• Not yet recruiting

NCT04864522: Phase 1: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma

Updated: May 25

MM BATs


NCT04864522: Phase 1: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs)


SLAMF7 BATS

Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs)


The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-SLAMF7 bispecific antibody armed activated T cells (SLAMF7 BATs/CS1 BATs) for patients with relapsed and/or refractory multiple myeloma. Patients receive 4 weekly doses and then 4 more doses every 2 weeks of SLAMF7 BATs by intravenous infusion. If patients have at least stable disease after these infusions, then they may receive additional infusions every 4 weeks up to a maximum of 21 infusions (including the initial 8 infusions).


Sponsor

University of Virginia


Location

United States, Virginia

 

ClinicalTrials.gov Identifier: NCT04864522


Official Title: Pilot Study of Anti-CD3 x Anti-SLAMF7 (Anti-CS-1) Bispecific Antibody Armed Activated T-Cells (SLAMF7 BATs/CS-1 BATs) in Relapsed/Refractory Multiple Myeloma

First Posted : April 29, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: SLAMF7 BATs

 


Posts Archive